MEMBRANOUS NEPHROPATHY

This study follows 500 adults with primary membranous nephropathy, a kidney disease that causes protein leakage and swelling. Researchers will track how well patients respond to treatments like rituximab or other monoclonal antibodies in real-world settings. The goal is to unders…

This study tests a new drug called HLX79, given together with rituximab, for people with active kidney inflammation (glomerulonephritis) from membranous nephropathy or lupus. About 24 adults will receive either HLX79 or a placebo, plus rituximab, to see if the combination is safe…

This study tests whether adding belimumab to rituximab works better than rituximab alone for people with membranous nephropathy, a kidney disease caused by the immune system attacking the kidneys. About 58 adults aged 18 to 75 with confirmed disease will receive either the combo …

This study tests whether artificial intelligence can help doctors personalize the dose of the drug rituximab for people with membranous nephropathy, an autoimmune kidney disease. About 120 adults with active disease will receive either standard rituximab or a dose adjusted by an …

This study helps people with certain kidney diseases (like nephrotic syndrome and FSGS) find clinical trials that might be a good fit for their specific condition. Researchers use advanced molecular testing to match each person's unique disease profile to targeted therapies being…

This study interviews 150 children, adults, and parents about their experiences with swelling caused by Nephrotic Syndrome. Researchers will use the information to create a survey that helps test new medications. No treatment is given; the goal is to better understand symptoms.

This study looks at blood samples from 86 people with membranous nephropathy, a kidney disease, and healthy volunteers. Researchers want to find out why some patients get better after B-cell depletion therapy while others do not. By analyzing different immune cells, they hope to …